HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (TARS) and raises the price target from $50 to $57.
February 28, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Tarsus Pharmaceuticals and increases the price target from $50 to $57.
The upgrade in the price target from $50 to $57 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Tarsus Pharmaceuticals' future performance. This positive analyst action is likely to instill investor confidence and could lead to a short-term uptick in TARS stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100